RecruitingNCT06807749

Adjuvant Treatment in Premenopausal Breast Cancer

PrEmenopausal bReaSt cancEr adjuVant thERapy Benefit According to OncotypE DX Test

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Enrollment

800 participants

Start Date

Dec 24, 2025

Study Type

OBSERVATIONAL

Conditions

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Summary

Multicentric retroprospective observational study to collect outcome in premenopausal breast cancer patients who undergone the 21-multigene assay Oncotype DX from 1st January 2013 to 31st December 2022 and adjuvant treatment.

Eligibility

Sex: FEMALEMax Age: 60 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with breast cancer early stage breast cancer (stage 1-3). The study is currently recruiting participants at 2 locations. People eligible for this study include women up to age 60 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.